Sickle Cell Disease and Thalassaemia
Conditions
Brief summary
Number of TEAEs, reported for each indication and age group separately, Number of adverse reactions, reported for each indication and age group separately
Detailed description
Annualised VOC rates, reported for each age group separately, Change in VOCs, reported for each age group separately, Change in Hb concentration, reported for each age group separately, Annualised number of hospitalisations, reported for each age group separately, Average length of stay of hospitalisations, reported for each age group separately, Change in Hb concentration, Number of RBC units transfused, reported for each indication separately, Change in RBC units transfused, reported for each indication separately
Interventions
Sponsors
Novo Nordisk A/S
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of TEAEs, reported for each indication and age group separately, Number of adverse reactions, reported for each indication and age group separately | — |
Secondary
| Measure | Time frame |
|---|---|
| Annualised VOC rates, reported for each age group separately, Change in VOCs, reported for each age group separately, Change in Hb concentration, reported for each age group separately, Annualised number of hospitalisations, reported for each age group separately, Average length of stay of hospitalisations, reported for each age group separately, Change in Hb concentration, Number of RBC units transfused, reported for each indication separately, Change in RBC units transfused, reported for each indication separately | — |
Countries
France, Germany, Greece, Italy, Spain
Outcome results
None listed